Methods for treating cancer

Abstract

The present invention relates to a method of treating a cancer in a patient.

1 . A method of treating a cancer in a patient, comprising administering to said patient a therapeutically effective amount of BT1718, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor, wherein the cancer is a colon cancer, and wherein the checkpoint inhibitor is a CTLA-4 antagonist. 
     
     
         2 - 14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 19.2 mg/m 2 . 
     
     
         16 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once a week. 
     
     
         17 . The method of  claim 1 , wherein the CTLA-4 antagonist is an anti-CTLA4 antibody. 
     
     
         18 . The method of  claim 1 , wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered by an intravenous infusion. 
     
     
         19 - 22 . (canceled) 
     
     
         23 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 14.4 mg/m 2 . 
     
     
         24 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 18.6 mg/m 2 . 
     
     
         25 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 14-24 mg/m 2 . 
     
     
         26 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 9-18 mg/m 2 . 
     
     
         27 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 1.5 weeks. 
     
     
         28 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 2 weeks. 
     
     
         29 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 2.5 weeks. 
     
     
         30 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 3 weeks. 
     
     
         31 . The method of  claim 1 , wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 4 weeks. 
     
     
         32 . The method of  claim 17 , wherein the anti-CTLA4 antibody is ipilimumab. 
     
     
         33 . The method of  claim 17 , wherein the anti-CTLA4 antibody is tremelimumab. 
     
     
         34 . The method of  claim 1 , wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with histidine. 
     
     
         35 . The method of  claim 1 , wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with sucrose. 
     
     
         36 . The method of  claim 1 , wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered by an about 1 hour intravenous infusion. 
     
     
         37 . The method of  claim 1 , wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with the CTLA-4 antagonist simultaneously or sequentially in separate unit dosage forms.